Ferguson Wellman Dumps 155,436 UNH Shares in Q2

Ferguson Wellman Capital Management significantly reduced its exposure to UnitedHealth Group (UNH) in Q2 2025, divesting $59.76 million in shares and cutting its holding to 0.18% of AUM. This move follows UNH's severe stock underperformance, down 41.5% over the past year, driven by withdrawn earnings guidance due to rising Medicare Advantage costs, leadership changes, multiple fraud allegations, and potential regulatory threats to its Optum Rx PBM business. Despite these challenges, UNH has refuted claims, reinstated a former CEO, and anticipates a return to growth by 2026.

Analysis

UnitedHealth Group (UNH) is facing a severe confluence of fundamental, legal, and governance crises, prompting significant institutional selling as evidenced by Ferguson Wellman Capital Management's divestment of $59.76 million in shares. This sale reduced UNH to a marginal 0.18% of the fund's AUM, signaling a sharp loss of confidence. The stock's performance reflects this distress, having fallen 41.5% over the past year and underperforming the S&P 500 by 52.8 percentage points. The negative catalysts are multifaceted: the company withdrew its full-year earnings guidance, citing an "unprecedented" rise in Medicare Advantage costs; the CEO abruptly resigned; and the company is reportedly under a criminal investigation by the Department of Justice for Medicare billing fraud. Furthermore, an executive order targeting Pharmacy Benefit Managers (PBMs) poses a direct threat to the Optum Rx segment, a key revenue driver that grew 15% in 2024. While the stock's forward P/E of 13.59 and 2.95% dividend yield might appear attractive, they are overshadowed by these risks. The company's counter-narrative rests on refuting the fraud allegations, appointing former CEO Stephen J. Hemsley to stabilize leadership, and projecting a return to growth in 2026 with a long-term EPS growth target of 13-16%, positioning the stock as a high-risk turnaround play.

Key Decisions for Investors

• Given the severity of the DOJ investigation, withdrawn guidance, and regulatory threats, risk-averse investors should consider reducing exposure until there is tangible resolution on these multiple fronts.
• For contrarian investors with a high-risk tolerance, the 41.5% stock price decline and low forward P/E may present a deep-value opportunity, contingent on the new leadership successfully navigating the legal and operational challenges.
• Investors should closely monitor any reinstatement of corporate guidance, developments in the DOJ investigation, and legislative outcomes impacting PBMs, as these will be the primary catalysts determining the stock's trajectory.